Conexeu Sciences Inc. (CNXU) Stock Price & Analysis
Conexeu Sciences Inc. (CNXU) closed at USD 3.95 on Thursday, October 15, 2026, up 8.37% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.65; the Oct 15, 2026 session ranged USD 3.4–4.05 on volume of 594,372 shares. Market capitalization is $111.42M, with a 52-week range of USD 3.05–18.79 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CNXU.md
Key facts (CNXU)
- Analysts: None (1 analysts), mean target USD 20 (range 20–20).
- Total return with dividends: 1Y -69.8% vs S&P 500 +18.1%; 5Y -72.6% vs S&P 500 +85.1%.
Analysts (CNXU)
Consensus None, 1 analysts; mean target USD 20 (low 20, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-22 | HC Wainwright & Co. | Initiated | Buy | $20 |
Total return (dividends reinvested) (CNXU)
| 1Y (from 2026-05-21) | 5Y (from 2026-05-18) | |
|---|---|---|
| Total return | -69.8% | -72.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 132.9% | 120.4% |
| Max drawdown | -81.6% (Jun 2026→Oct 2026) | -79.7% (Jun 2026→Sep 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 3.95 |
|---|---|
| Change | ▲ 8.37% (up) |
| Previous Close | USD 3.65 |
| Open | USD 3.65 |
| Day Range | USD 3.4 – 4.05 |
| 52-Week Range | USD 3.05 – 18.79 |
| Volume | 594,372 shares |
| Market Cap | $111.42M |
| Exchange | NCM |
Technical Analysis (CNXU)
Nexqual's technical model rates CNXU "SELL" based on 1 bullish and 4 bearish signals across 102 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.89 (neutral) |
| vs SMA50 | Below (USD 5.62) |
| MACD | -0.53 (negative) |
Analyst Ratings (CNXU)
Wall Street analysts rate CNXU "None" based on 1 analysts, with a mean price target of USD 20 (range USD 20–20), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 20 |
| High Target | USD 20 |
| Low Target | USD 20 |
Earnings (CNXU)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-07-31 | USD -0.29 vs est -0.1 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (CNXU)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -332.94% |
| Debt / Equity | 0.08 |
| Current Ratio | 5.31 |
| Total Cash | $1.97M |
| Total Debt | $453,802 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (CNXU)
Nexqual rates Conexeu Sciences Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $2M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$11M (TTM) |
| Efficiency | Critical — ROE -333%, ROA -170.7% |
Ownership (CNXU)
| Insider Ownership | +52.06% |
|---|---|
| Institutional Ownership | +7.59% |
| Shares Outstanding | 28.21M |
| Float | 15.54M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (CNXU)
Conexeu Sciences Inc. is led by Miles D. Harrison (age 60), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO & Director | Miles D. Harrison (age 60) |
|---|---|
| Founder, Chief Commercial Officer & Director | David R. Bogart (age 55) |
| Founder & Chief Scientific Officer | Claudia Chavez-Munoz (age 45) |
| CFO, Corporate Secretary & Treasurer | Stephen D. Inouye (age 64) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt